KR920006781B1 - 디하이드로 피리다진온 유도체를 제조하는 방법 - Google Patents

디하이드로 피리다진온 유도체를 제조하는 방법 Download PDF

Info

Publication number
KR920006781B1
KR920006781B1 KR1019850000179A KR850000179A KR920006781B1 KR 920006781 B1 KR920006781 B1 KR 920006781B1 KR 1019850000179 A KR1019850000179 A KR 1019850000179A KR 850000179 A KR850000179 A KR 850000179A KR 920006781 B1 KR920006781 B1 KR 920006781B1
Authority
KR
South Korea
Prior art keywords
methyl
phenyl
dihydro
compound
cyanoguanidino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019850000179A
Other languages
English (en)
Korean (ko)
Other versions
KR850005417A (ko
Inventor
앤토니 슬래터 로버트
Original Assignee
스미스 클라인 앤드 프렌취 라보라토리스 리미티드
데비드 마틴 워터스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미스 클라인 앤드 프렌취 라보라토리스 리미티드, 데비드 마틴 워터스 filed Critical 스미스 클라인 앤드 프렌취 라보라토리스 리미티드
Publication of KR850005417A publication Critical patent/KR850005417A/ko
Application granted granted Critical
Publication of KR920006781B1 publication Critical patent/KR920006781B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
KR1019850000179A 1984-01-13 1985-01-12 디하이드로 피리다진온 유도체를 제조하는 방법 Expired KR920006781B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds
GB8400863 1984-01-13

Publications (2)

Publication Number Publication Date
KR850005417A KR850005417A (ko) 1985-08-26
KR920006781B1 true KR920006781B1 (ko) 1992-08-17

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850000179A Expired KR920006781B1 (ko) 1984-01-13 1985-01-12 디하이드로 피리다진온 유도체를 제조하는 방법

Country Status (31)

Country Link
US (1) US4654342A (enExample)
EP (1) EP0150937B1 (enExample)
JP (3) JPS60158181A (enExample)
KR (1) KR920006781B1 (enExample)
CN (1) CN85101722A (enExample)
AT (1) ATE37179T1 (enExample)
AU (1) AU572252B2 (enExample)
CA (2) CA1251209A (enExample)
CS (1) CS248731B2 (enExample)
DD (1) DD231350A5 (enExample)
DE (1) DE3564941D1 (enExample)
DK (1) DK162519C (enExample)
ES (3) ES8607949A1 (enExample)
FI (1) FI850140A7 (enExample)
GB (1) GB8400863D0 (enExample)
GR (1) GR850068B (enExample)
HU (1) HU193591B (enExample)
IE (1) IE57969B1 (enExample)
IL (1) IL74031A (enExample)
JO (1) JO1351B1 (enExample)
MY (1) MY100124A (enExample)
NO (1) NO850129L (enExample)
NZ (1) NZ210816A (enExample)
PH (1) PH22136A (enExample)
PL (1) PL147123B1 (enExample)
PT (1) PT79819B (enExample)
RO (1) RO92607A (enExample)
SU (1) SU1396963A3 (enExample)
WO (1) WO1985003076A1 (enExample)
ZA (1) ZA85251B (enExample)
ZW (1) ZW385A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
EP1377282B1 (en) * 2001-02-27 2006-08-16 MIGENIX Corp. Aryl-n-cyanoguanidines and methods related thereto
CN1585641A (zh) * 2001-11-05 2005-02-23 默克专利有限公司 亚肼基－丙二腈化合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
JP5312034B2 (ja) * 2005-11-14 2013-10-09 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 無症候性（潜在性）心不全の治療のためのｐｄｅｉｉｉ阻害剤の使用
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL2370070T3 (pl) 2008-11-25 2014-02-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN107090016A (zh) 2011-03-01 2017-08-25 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
DK3021832T3 (da) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
ES2593210T3 (es) 2013-12-04 2016-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
EP0030835B1 (en) * 1979-12-05 1983-05-11 Morishita Pharmaceutical Co. Ltd. Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
DE3263497D1 (en) * 1981-03-04 1985-06-20 Ciba Geigy Ag Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants

Also Published As

Publication number Publication date
CA1260471A (en) 1989-09-26
AU572252B2 (en) 1988-05-05
ES539446A0 (es) 1986-06-01
EP0150937B1 (en) 1988-09-14
DK162519B (da) 1991-11-11
SU1396963A3 (ru) 1988-05-15
WO1985003076A1 (en) 1985-07-18
DK162519C (da) 1992-03-30
PH22136A (en) 1988-06-01
FI850140L (fi) 1985-07-14
IL74031A (en) 1988-07-31
ES8703846A1 (es) 1987-03-01
IL74031A0 (en) 1985-04-30
HU193591B (en) 1987-11-30
DD231350A5 (de) 1985-12-24
ES549629A0 (es) 1987-03-01
GR850068B (enExample) 1985-05-03
CN85101722A (zh) 1987-01-31
PL147123B1 (en) 1989-04-29
US4654342A (en) 1987-03-31
ES8607949A1 (es) 1986-06-01
HUT37128A (en) 1985-11-28
JO1351B1 (en) 1986-11-30
ZW385A1 (en) 1985-08-07
NO850129L (no) 1985-07-15
ZA85251B (en) 1986-08-27
PL251516A1 (en) 1985-12-17
JPS63313775A (ja) 1988-12-21
PT79819B (en) 1987-01-07
JPS60158181A (ja) 1985-08-19
CS248731B2 (en) 1987-02-12
KR850005417A (ko) 1985-08-26
DE3564941D1 (en) 1988-10-20
ATE37179T1 (de) 1988-09-15
AU3761185A (en) 1985-07-18
EP0150937A2 (en) 1985-08-07
MY100124A (en) 1989-12-18
PT79819A (en) 1985-02-01
IE57969B1 (en) 1993-06-02
NZ210816A (en) 1987-06-30
RO92607A (ro) 1987-11-30
DK9185D0 (da) 1985-01-08
CA1251209A (en) 1989-03-14
IE850069L (en) 1985-07-13
CA1260471C (enExample) 1989-09-26
FI850140A7 (fi) 1985-07-14
FI850140A0 (fi) 1985-01-11
DK9185A (da) 1985-07-14
GB8400863D0 (en) 1984-02-15
EP0150937A3 (en) 1985-08-21
ES554965A0 (es) 1987-07-01
JPS63313776A (ja) 1988-12-21
ES8706645A1 (es) 1987-07-01

Similar Documents

Publication Publication Date Title
KR920006781B1 (ko) 디하이드로 피리다진온 유도체를 제조하는 방법
US6531473B2 (en) Method of treatment using arylalkylpyridazinones
CA2003690A1 (en) Chemical compounds
DK159431B (da) 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
KR100673638B1 (ko) 아릴 알카노일피리다진류
JPS6136282A (ja) 窒素を含む複素環式化合物からなる医薬品とその製造方法
US4946842A (en) Novel guanidino pyridazinones as cardiac stimulants
US5101072A (en) Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
JP3878237B2 (ja) アリールアルキル−チアジアジノン誘導体
KR910003153B1 (ko) 7-피페리디노-1,2,3,5-테트라하이드로이미다조[2,1-b]퀴나졸린-2-온의 제조방법
EP0201988A2 (en) Dihydropyridazinone derivatives
US4766123A (en) Methylamidine compounds
PL103682B1 (pl) Sposob wytwarzania nowych pochodnych indazoliloksy-4-propanoloaminy
US5681843A (en) Parabanic acid derivatives
HU193067B (en) Process for the production of new pyridazinon-derivatives and of their salts
DE10064997A1 (de) Benzoylpyridazine
EP0199465A2 (en) Cyanoalkanimidamido compounds
JP4546082B2 (ja) 心臓疾患及びアレルギーの治療のためのｐｄｅｉｖ阻害作用及びｔｎｆ拮抗作用を有する４−（ベンジリデンアミノ）−３−（メチルスルファニル）−４ｈ−１，２，４−トリアジン−５−オン誘導体
DE3346640A1 (de) Neue imidazolderivate, deren herstellung und diese verbindungen enthaltende arzneimittel
US4632924A (en) 5-(4-substituted)phenyl-2-pyrazinones
US4962110A (en) Pyridazinone derivatives
JP2003504358A (ja) ベンゾイルピリダジン
EP0197664A2 (en) 2-Aminopyrimidinone derivatives
JPS61212583A (ja) ２‐アミノピリミジノン誘導体
JPS61221177A (ja) シアノアルカンイミドアミド化合物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19950818

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19950818